Pall — Q2 FY2014 Earnings Presentation
17 slides from Pall's earnings presentation, Feb 27, 2014
Slide 1: Q2 FY 2014 Financial Results
Better Lives. Better Planet.SM © 2014 Pall Corporation Q2 FY 2014 Financial Results February 27, 2014 Exhibit 99.2
Slide 2: Forward-looking statements
2 The matters discussed in this presentation contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Results for the second quarter of fiscal year 2014 are preliminary until our Form 10-Q is filed with the Securities and Exchange Commission on or befo
Slide 3: Conference Call Information
3 Conference Call Information Dial-In Toll-Free: 855.356.7268 International: 706.634.1981 Replay Toll-Free: 855.859.2056 International: 404.537.3406 Conference ID: 11904826 Internet: www.pall.com/investor
Slide 4: Q2 Overview
4 Q2 Overview Solid Q2 performance – EPS up 12% – Operating margin up 120 bps Similar market trends Increasing order rates Completed acquisition of ATMI LifeSciences On plan for FY14 All remarks in this presentation are on a “Continuing Operations” basis, which excludes the results of the Bl
Slide 5: ATMI LifeSciences Key Products
5 ATMI LifeSciences Key Products Innovative BioReactor Solutions. iCELLis® and Xpansion™ shown World’s largest installed base and broadest range of single-use mixing systems. PadMixer™ and Magnetic Mixer shown Strategic Highlights Single-use technology leader Bioreactors, mixers, storage systems
Slide 6: Q2 Financial Summary
6 $662 $677 $- $200 $400 $600 $800 Revenue % Growth Excluding FX FY 2013 FY 2014 Q2 Financial Summary Dollars in millions, except EPS data A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix. 17.0% 18.2% 10.0% 15.0% 20.0% Operat
Slide 7: Q2 Sales by Segment
7 Life Sciences Consumables $319 +7% Industrial Consumables $270 +2% Industrial Systems $54 -9% Life Sciences Systems $34 +20% 40% 47% 8% 5% Q2 Sales by Segment Dollars in millions Percentages outside pie charts and in box represent sales change excluding FX Percentages inside pie charts represent p
Slide 8: Q2 Life Sciences Segment Performance
8 Q2 Life Sciences Segment Performance Dollars in millions excluding FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix 0% 30% 60% 56.6% -180 bps 58.4% 0% 30% 60% 25.7% +60 bps 25.1% FY 2013 FY 2014 Gross Margin Segment Marg
Slide 9: Q2 Industrial Segment Performance
9 Q2 Industrial Segment Performance Dollars in millions excluding FX A reconciliation of Non-GAAP Financial Measures in this presentation to their GAAP Counterparts is provided in the Appendix Gross Margin Segment Margin Process Technologies consumables: 0% Aerospace consumables: -12% Microele
Slide 10: Q2 Cash Flow and Working Capital
10 Q2 Cash Flow and Working Capital YTD FY14 YTD FY13 Operating Cash Flow 206$ 89$ CapEx (35) (42) Free Cash Flow 171$ 47$ Other Significant Sources/(Uses) of Cash: Proceeds from sale of assets 2$ 542$ Acquisition of businesses (5) - Dividends (58) (53) Borrowing/Repayment under Financing Facilities
Slide 11: FY 2014 Outlook Update
11 Total Revenue Low to mid single digit growth Segment Revenue Life Sciences: Mid to high single digit growth Industrial: Flat −Modest consumables growth Pro Forma EPS $3.35 – $3.45 Maintaining midpoint of the EPS range, after absorbing approximately 10 cent headwind from acquisition of A
Slide 12: Appendix
Better Lives. Better Planet.SM © 2014 Pall Corporation Appendix
Slide 13: Q2 Earnings and FY 2014 Estimates from Continuing Operations Reconciliation
13 Appendix: Q2 Earnings and FY 2014 Estimates from Continuing Operations Reconciliation of Non-GAAP Financial Measures Diluted EPS from continuing operations as reported 0.75$ 0.70$ 3.26$ Discrete Items: ROTC after pro forma tax effect 0.07 0.03 0.14 Tax Adjustments - - - Interest Adjustments after
Slide 14: Q2 Life Sciences Sales By Market & Technology Reconciliation
14 Appendix: Q2 Life Sciences Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q2 FY14 Q2 FY14 Estimated Impact of FX Q2 FY14 Estimate Excluding FX Q2 FY13 % Change Excluding FX Consumables Sales: BioPharmaceuticals 218,625$ (1,387)$ 220,012$ 201,657$ 9.1% Food & Beverage 4
Slide 15: Q2 Industrial Sales By Market & Technology Reconciliation
15 Appendix: Q2 Industrial Sales By Market & Technology Reconciliation of Non-GAAP Financial Measures Q2 FY14 Q2 FY14 Estimated Impact of FX Q2 FY14 Estimate Excluding FX Q2 FY13 % Change Excluding FX Consumables Sales: Process Technologies 139,664$ (3,070)$ 142,734$ 143,146$ -0.3% Aerospace 53,322
Slide 16: Q2 Orders by Segment Reconciliation
16 Appendix: Q2 Orders by Segment Reconciliation of Non-GAAP Financial Measures Dollars in thousands Q2 FY14 Q2 FY14 Estimated Impact of FX Q2 FY14 Estimate Excluding FX Q2 FY13 % Change Excluding FX Life Sciences Orders: Consumables 363,351$ (2,833)$ 366,184$ 322,731$ 13.5% Systems 31,458 (691) 32,
Slide 17: Q2 Operating Profit Reconciliation
17 Appendix: Q2 Operating Profit Reconciliation of Non-GAAP Financial Measures Operating Profit Q2 FY14 Q2 FY13 Life Sciences segment profit 90,856$ 82,477$ Industrial segment profit 46,891 48,104 Total segment profit 137,747$ 130,581$ General corporate expenses (14,766) (18,026) Operating profit 12